Takeda Pharmaceutical Company Limited

Kazuko Yonemori

Satoshi Yamamoto

Junya Shirai

Yoshiyuki Fukase

Atsuko Ochida

Yoshihide Tomata

Ayumu Sato

Shinichi Imamura

Tzu-Tshin Wong

Yasuhiro Hirata

Osamu Kurasawa

Tsuneo Yasuma

Tsuneo Oda

Makoto Kamata

Takuto Kojima

Masataka Murakami

Yasutomi Asano

Shuji Kitamura

Yasufumi Miyamoto

Yuta Tanaka

Naoki Iwamura

Ryosuke Arai

Bunnai Saito

Osamu Sano

Zenichi Ikeda

Ikuo Fujimori

Tohru Yamashita

Tomoya Yukawa

Hideki Hirose

Nobuyuki Matsunaga

Asato Kina

Hideyuki Nakagawa

Ryo Mizojiri

Takuya Fujimoto

Shotaro Miura

Kyoko Toyofuku

Mitsunori Kouno

Ryokichi Koyama

Arai Ryosuke

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Heterocyclic compound

The present invention provides a heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): whereinAr is a the partial structure (1) to the partial structure (5),Q is a bivalent group selected from the group consisting of (Ia)-(If), andB is a ring optionally having substituent(s),or a salt thereof.

A heterocyclic compound having an ROR&#x3b3;t inhibitory activity, which is a compound of formula (I) or a salt thereof is provided. The compound has ring A, which is an optionally substituted cyclic group and is bound to a pyrazole ring though Q. Q is a bond, optionally substituted Calkylene, optionally substituted Calkenylene, or optionally substituted Calkynylene. Ris a substituent. Ring B is a thiazole ring, an isothiazole ring or a dihydrothiazole ring, each of which is optionally further substituted by a substituent in addition to R. Ris an optionally substituted cyclyl-carbonyl-Calkyl group, an optionally substituted aminocarbonyl-Calkyl group, an optionally substituted cyclyl-Calkyl group, an optionally substituted cyclyl-Calkylamino-carbonyl group, an optionally substituted aminocarbonyl-Calkenyl group, an optionally substituted Calkylcarbonylamino-Calkyl group, an optionally substituted cyclyl-aminocarbonyl group, an optionally substituted cyclyl-carbonyl group or an optionally substituted non-aromatic heterocyclic group.

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Bicyclic compound

The present invention provides a fused heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I'): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N&#x2032;-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a thereof.

Condensed heterocyclic compound

Growing community of inventors

Fujisawa, Japan

Kazuko Yonemori